Giansiracusa J E, Donaldson M S, Koonce M L, Lefton T E, Ruoff G E, Brooks C D
South Med J. 1977 Jan;70(1):49-52. doi: 10.1097/00007611-197701000-00022.
In a double-blind, multiclinic study, 437 patients with osteoarthritis were treated sequentially with ibuprofen, 1,800 mg/day, and placebo, or with aspirin, 3,600 mg/day, and placebo. Each treatment was given for four weeks. Considering relief of pain, ability to function, and general well-being, the patients preferred drug to placebo, usually by a statistically significant margin. Combined results showed no significant differences between ibuprofen and aspirin. Patients' evaluations of exercise-related pain, ability to perform a selected activity, and total discomfort and disability, and physicians' evaluations of discomfort and disability, all favored drug over placebo, and the differences were significant for a number of endpoints. The results indicated ibuprofen, 1,800 mg/day, offers about the same antiarthritic benefit as aspirin, 3,600 mg/day. Both drugs are superior to placebo. The incidence of gastrointestinal complaints with ibuprofen was similar to that with placebo and significantly lower than that with aspirin.
在一项双盲、多中心研究中，437例骨关节炎患者先后接受布洛芬（1800毫克/天）加安慰剂治疗，或阿司匹林（3600毫克/天）加安慰剂治疗。每种治疗持续四周。从疼痛缓解、功能能力和总体健康状况来看，患者通常在统计学上更倾向于药物而非安慰剂。综合结果显示布洛芬和阿司匹林之间无显著差异。患者对运动相关疼痛、进行特定活动的能力、总体不适和残疾程度的评估，以及医生对不适和残疾程度的评估，均表明药物优于安慰剂，且在多个终点指标上差异显著。结果表明，1800毫克/天的布洛芬与3600毫克/天的阿司匹林具有大致相同的抗关节炎益处。两种药物均优于安慰剂。布洛芬引起胃肠道不适的发生率与安慰剂相似，且显著低于阿司匹林。
